US4156725A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bacteriostatic biologically active compositions
Assignee: SmithKline Beecham Corp
•
Filing: 1977-05-02
•
Granted: 1979-05-29
•
Expires: 1997-05-02
Abstract
Abstract Novel pteridines of formula (I), ##STR1## wherein R is an optionally substituted phenoxyalkyl group, and R 1 and R 2 are the same or different and each is a lower alkyl group or R 1 and R 2 , together with the carbon atom in the pteridine ring structure, form a spirocycloalkyl ring system having 4 to 6 carbon atoms outside the pteridine ring structure, and their method of preparation. The above compounds have bacteriostatic activity.
Inventors
- 👤 Hamish C. S. Wood
- 👤 Kyuji Ohta
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 08:40
CPC Classifications
C; C07; C07D; C07D239/00; C07D239/02; C07D239/24; C07D239/28; C07D239/46; C07D239/48
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
100 words
A pharmaceutical formulation comprising an effective bacteriostatic amount of a compound of formula (I) ##STR7## a tautomeric form thereof or a pharmaceutically acceptable salt thereof, wherein R is phenoxyalkyl or phenoxyalkyl substituted with methoxy, chloro or methyl, wherein the alkyl of the phenoxyalkyl is lower alkyl, and R 1 and R 2 are the same or different and each is lower alkyl or R 1 and R 2 , together with the carbon atom in the ring structure, form a spirocycloalkyl ring system having 4 to 6 carbon atoms outside the pteridine ring structure and a pharmaceutically acceptable carrier therefore.
Claim 2
Dependent Claim
100 words
A pharmaceutical formulation comprising an effective bacteriostatic amount of a compound of formula (I) ##STR7## a tautomeric form thereof or a pharmaceutically acceptable salt thereof, wherein R is phenoxyalkyl or phenoxyalkyl substituted with methoxy, chloro or methyl, wherein the alkyl of the phenoxyalkyl is lower alkyl, and R 1 and R 2 are the same or different and each is lower alkyl or R 1 and R 2 , together with the carbon atom in the ring structure, form a spirocycloalkyl ring system having 4 to 6 carbon atoms outside the pteridine ring structure and a pharmaceutically acceptable carrier therefore.
Claim 3
Dependent Claim
15 words
The formulation of claim 1 in which R 1 and R 2 are lower alkyl.
Claim 4
Dependent Claim
14 words
The formulation of claim 2 in which R 1 and R 2 are ethyl.
Claim 5
Dependent Claim
83 words
A pharmaceutical formulation comprising an effective bacteriostatic amount of a compound of formula (I) ##STR8## a tautomeric form thereof or a pharmaceutically acceptable salt thereof, wherein R is phenoxymethyl and R 1 and R 2 are the same or different and each is lower alkyl or R 1 and R 2 , together with the carbon atom in the ring structure, form a spirocycloalkyl ring system having 4 to 6 carbon atoms outside the pteridine ring structure and a pharmaceutically acceptable carrier therefore.
Claim 6
Dependent Claim
83 words
A pharmaceutical formulation comprising an effective bacteriostatic amount of a compound of formula (I) ##STR8## a tautomeric form thereof or a pharmaceutically acceptable salt thereof, wherein R is phenoxymethyl and R 1 and R 2 are the same or different and each is lower alkyl or R 1 and R 2 , together with the carbon atom in the ring structure, form a spirocycloalkyl ring system having 4 to 6 carbon atoms outside the pteridine ring structure and a pharmaceutically acceptable carrier therefore.
Claim 7
Dependent Claim
15 words
The formulation of claim 4 in which R 1 and R 2 are each methyl.
Claim 8
Dependent Claim
86 words
A pharmaceutical formulation comprising an effective bacteriostatic amount of a compound of formula (I) ##STR9## a tautomeric form thereof or a pharmaceutically acceptable salt thereof, wherein R is p-methoxyphenoxymethyl, p-chlorophenoxymethyl) or p-methylphenoxymethyl, and R 1 and R 2 are the same or different and each is lower alkyl or R 1 and R 2 , together with the carbon atom in the ring structure, form a spirocycloalkyl ring system having 4 to 6 carbon atoms outside the pteridine ring structure and a pharmaceutically acceptable carrier therefore.
Claim 9
Dependent Claim
86 words
A pharmaceutical formulation comprising an effective bacteriostatic amount of a compound of formula (I) ##STR9## a tautomeric form thereof or a pharmaceutically acceptable salt thereof, wherein R is p-methoxyphenoxymethyl, p-chlorophenoxymethyl) or p-methylphenoxymethyl, and R 1 and R 2 are the same or different and each is lower alkyl or R 1 and R 2 , together with the carbon atom in the ring structure, form a spirocycloalkyl ring system having 4 to 6 carbon atoms outside the pteridine ring structure and a pharmaceutically acceptable carrier therefore.
Claim 10
Dependent Claim
14 words
The formulation of claim 6 in which R 1 and R 2 are methyl.
References Cited (Backward Citations)
US3635978A
Cited
US3810893A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-05-28 | 1982-11-27 | 1983-05-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-05-28 | 1986-11-27 | 1987-05-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-05-28 | 1990-11-27 | 1991-05-29 | $7700.00 | Window Closed / Lapsed |